Skip to main content
Top

29-01-2025 | Breast Cancer | Breast Oncology

Ongoing Symptoms and Concerns Experienced by Low-Risk Breast Cancer Survivors Following Active Treatment

Authors: Jessica R. Schumacher, PhD, Jennifer L. Tucholka, PA-C, BS, Catherine R. Breuer, MS, Grace H. McKinney, MMSc, Courtney Maxcy, MPH, Trista J. Stankowski-Drengler, MD, MS, Nicholas A. Marka, MS, Bret M. Hanlon, PhD, Kristine L. Kwekkeboom, PhD, RN, FAAN,, Amye J. Tevaarwerk, MD, James E. Haine, MD, Heather B. Neuman, MD, MS

Published in: Annals of Surgical Oncology

Login to get access

Abstract

Introduction

Little is known about the symptom burden of breast cancer survivors with early-stage disease. Many studies have focused on symptoms of patients who are undergoing or recently completed systemic therapy. However, with the increased use of Oncotype DX, the proportion of early-stage hormone receptor-positive patients who undergo chemotherapy has declined, making existing studies of the symptom experience less useful for these patients.

Objective

The aim of this study was to assess symptom burden for early-stage breast cancer survivors.

Methods

Eligible survivors had stage I–II, estrogen receptor (ER)- or progesterone receptor (PR)-positive and HER2neu-negative breast cancer, did not receive chemotherapy, were 6 months–5 years post-diagnosis, and were cancer-free. Survivors were enrolled at the University of Wisconsin Breast Center follow-up visits and were emailed a link to a patient-reported outcomes (PRO) survey. Survey domains were informed by American Cancer Society/American Society of Clinical Oncology (ACS/ASCO) survivorship guidelines and survivor/provider stakeholders. The prevalence of clinically significant symptoms are reported.

Results

Overall, 98 patients participated. On average, participants were 61.3 years of age (standard deviation [SD] 11.5) and 2.5 years post-diagnosis (SD 1.2); 71.3% underwent breast-conserving surgery. The average item-level missingness rate was low (2.0%). Most survivors (86.2%) experienced symptoms (38.8% reporting one to two symptoms; 47.9% reporting more than three symptoms).

Conclusions

Early-stage breast cancer survivors report a high symptom burden. Given nearly 50% of survivors report more than three symptoms, many topics may not be discussed or addressed during time-limited follow-up visits. Some symptoms, such as sexual health, may be less feasible to address in-clinic given their complex/sensitive nature. Use of PROs allows for a comprehensive evaluation and identification of unrecognized needs, representing an opportunity to improve survivorship care.
Appendix
Available only for authorised users
Literature
1.
go back to reference American Cancer Society. Cancer facts and figures 2021. Atlanta: American Cancer Society; 2021. American Cancer Society. Cancer facts and figures 2021. Atlanta: American Cancer Society; 2021.
5.
go back to reference Neuman HB, Schumacher JR, Edge SB, et al. The influence of anatomic stage and receptor status on first recurrence for breast cancer within five years (AFT-01). Cancer. 2023;129(9):1351–60.CrossRefPubMed Neuman HB, Schumacher JR, Edge SB, et al. The influence of anatomic stage and receptor status on first recurrence for breast cancer within five years (AFT-01). Cancer. 2023;129(9):1351–60.CrossRefPubMed
27.
go back to reference Neuman HB, Kwekkeboom KL, Tevaarerk AJ, Phelps K, Tucholka JL, Maxcy C, Breuer CR, Schumacher JR. Engaging survivor and oncologist stakeholders to develop a patient-reported outcome assessment to use as a component of survivorship care. Support Care Cancer. 2024;33:9CrossRefPubMed Neuman HB, Kwekkeboom KL, Tevaarerk AJ, Phelps K, Tucholka JL, Maxcy C, Breuer CR, Schumacher JR. Engaging survivor and oncologist stakeholders to develop a patient-reported outcome assessment to use as a component of survivorship care. Support Care Cancer. 2024;33:9CrossRefPubMed
31.
go back to reference Youngwirth LM, Boughey JC, Hwang ES. Surgery versus monitoring and endocrine therapy for low-risk DCIS: the COMET trial. Bull Am Coll Surg. 2017;102(1):62–3.PubMed Youngwirth LM, Boughey JC, Hwang ES. Surgery versus monitoring and endocrine therapy for low-risk DCIS: the COMET trial. Bull Am Coll Surg. 2017;102(1):62–3.PubMed
32.
go back to reference Armer JM, Radina ME, Porock D, Culbertson SD. Predicting breast cancer-related lymphedema using self-reported symptoms. Clinical trial comparative study randomized controlled trial. Nurs Res. 2003;52(6):370–9.CrossRefPubMed Armer JM, Radina ME, Porock D, Culbertson SD. Predicting breast cancer-related lymphedema using self-reported symptoms. Clinical trial comparative study randomized controlled trial. Nurs Res. 2003;52(6):370–9.CrossRefPubMed
39.
Metadata
Title
Ongoing Symptoms and Concerns Experienced by Low-Risk Breast Cancer Survivors Following Active Treatment
Authors
Jessica R. Schumacher, PhD
Jennifer L. Tucholka, PA-C, BS
Catherine R. Breuer, MS
Grace H. McKinney, MMSc
Courtney Maxcy, MPH
Trista J. Stankowski-Drengler, MD, MS
Nicholas A. Marka, MS
Bret M. Hanlon, PhD
Kristine L. Kwekkeboom, PhD, RN, FAAN,
Amye J. Tevaarwerk, MD
James E. Haine, MD
Heather B. Neuman, MD, MS
Publication date
29-01-2025
Publisher
Springer International Publishing
Published in
Annals of Surgical Oncology
Print ISSN: 1068-9265
Electronic ISSN: 1534-4681
DOI
https://doi.org/10.1245/s10434-025-16959-w
SPONSORED

Mastering chronic pancreatitis pain: A multidisciplinary approach and practical solutions

  • Webinar | 06-02-2024 | 20:00 (CET)

Severe pain is the most common symptom of chronic pancreatitis. In this webinar, experts share the latest insights in pain management for chronic pancreatitis patients. Experts from a range of disciplines discuss pertinent cases and provide practical suggestions for use within clinical practice.

Sponsored by:
  • Viatris
Developed by: Springer Healthcare
Watch now